or
Remember me
Back
Solid news today with AGN announcing its Phase 2b clinical study of Ifenprodil for chronic cough to begin in Q3 2023!
Thinking there is a good chance for AGN to receive orphan drug designation for ifenprodil for chronic cough given the positive feedback from the US FDA alongside receiving ODD for Ifenprodil for IPF.
A daily snapshot of everything from market open to close.